
FibroBiologics fell 87.4% from $7.36 to $0.93, behind the S&P 500's +12.3%. Its worst day was Mar 31 (−42.1%), and its low came Jul 27 at $0.63.
Nov 14, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
FibroBiologics shares fell 23.5%, while the S&P 500 rose 1.5%.
−23.5% · S&P 500 +1.5%
Story events cover the past 12 months · Times ET
FibroBiologics shares fell 33.1%, while the S&P 500 fell 0.2%.
−33.1% · S&P 500 −0.2%
FibroBiologics shares rose 32.3%, while the S&P 500 fell 0.3%.
+32.3%, the year's best day · S&P 500 −0.3%
EPS of $-0.60 beat the $-2.00 estimate on $0.00 revenue.
−1.6% · S&P 500 +0.8%
FibroBiologics closed at its highest level of the year, 18.2% above where the year started.
+3.8% · S&P 500 −1.3%
FibroBiologics shares fell 42.1%, while the S&P 500 rose 2.9%.
−42.1%, the year's worst day, on 9M shares, the year's heaviest volume · S&P 500 +2.9%
EPS of $-1.33 beat the $-1.33 estimate on $0.00 revenue.
+10.6% · S&P 500 +0.3%
EPS of $-0.66 beat the $-0.93 estimate on $0.00 revenue.
+12.9% · S&P 500 +1.4%
FibroBiologics shares rose 22.7%, while the S&P 500 fell 0.7%.
+22.7% · S&P 500 −0.7%
Where it ended: a close of $0.93 on Nov 13, 2026. Up next: Q3 2026 earnings on Nov 27, 2026 (EPS est. $-0.63).
Nothing in the past 12 months.
All FBLG dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for FBLG and SPY from Benzinga historical bars. Not investment advice.